Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Objective: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. Design: Pharmacoepidemiological cohort study. Methods/settings: From nationwide registers, we identified patients with an in-hospital or outpatient-clinic AF diagnosis who claimed a prescription of dabigatran 110 or 150 mg, or vitamin K antagonist (VKA), between 22 August and 31 December 2011. HRs of thromboembolic events (ischaemic stroke, transitory ischaemic attack and peripheral artery embolism) and bleedings were estimated using Cox regression analyses in all patients and stratified by previous VKA use. Results: Overall, 1612 (3.1%) and 1114 (2.1%) patients claimed a prescription of dabigatran 110 and 150 mg, and 49640 (94.8%) of VKA. Patients treated with dabigatran 150 mg were younger with less comorbidity than those treated with dabigatran 110 mg and VKA, as were VKA naïve patients compared with previous VKA users. Recommendations set by the European Medicine Agency (EMA) for dabigatran were met in 90.3% and 55.5% of patients treated with 110 and 150 mg. Patients treated with 150 mg dabigatran, who did not fulfil the recommendations by EMA, were >80 years, patients with liver or kidney disease, patients with previous bleeding. Compared with VKA, the thromboembolic risk associated with dabigatran 110 and 150 mg was HR 3.52 (1.40 to 8.84) and 5.79 (1.81 to 18.56) in previous VKA users, and HR 0.95(0.47 to 1.91) and 1.14(0.60 to 2.16) in VKA naïve patients. Bleeding risk was increased in previous VKA users receiving dabigatran 110 mg, but not in patients with 150 mg dabigatran, nor in the VKA naïve users. Conclusions: Deviations from the recommended use of dabigatran were frequent among patients treated with 150 mg. With cautious interpretation, dabigatran use in VKA naïve patients seems safe. Increased risk of thromboembolism and bleeding with dabigatran among previous VKA users was unexpected and may reflect patient selection and ‘drug switching’ practices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 5×
“In the overall cohort, we unexpectedly found that the adjusted risk of thromboembolic events was increased among users of both doses of dabigatran.(4) Among VKA naive subjects, the risk of thromboembolic events was comparable with VKA with both doses of dabigatran, but increased in dabigatran users who had previously…”
BackgroundInfluentialRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citationHart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citation2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Self-citationvon Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.012 · Cited by 2,698
Guidelines for the management of atrial fibrillation
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,747
Self-citationOlesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationEikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855 · cited 7×
“In addition, our definition of bleeding varies from the definition used in the RE-LY trial,(4) but at least it includes serious bleedings leading to hospitalisation, as has been used previously.(18)”
BackgroundMethodInfluentialThe Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689 · cited 1×
“Dabigatran has fewer interactions with food and drugs than VKA and does not need monitoring of its anticoagulant effect.(5) Moreover, dabigatran 150 mg twice daily was superior to VKA in preventing stroke, with an additional overall reduction of cardiovascular mortality, and without increasing the risk of major bleedi…”
BackgroundThe Danish prescription registries.
Gaist, D., Sørensen, H. T., & Hallas, J. (1997) · PubMed · Cited by 570
Lip, G., Lindhardsen, J., Lane, D., Ahlehoff, O., Hansen, M., Raunsø, J., Tolstrup, J., Hansen, P., Gislason, G., Torp-Pedersen, C., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-05-0364 · Cited by 428
Self-citationNational Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. S., & Alexander, G. C. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.967299 · Cited by 311
LIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
Ezekowitz, M. D., Wallentin, L., Connolly, S. J., Parekh, A., Chernick, M. R., Pogue, J., Aikens, T. H., Yang, S., Reilly, P. A., Lip, G. Y. H., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.973735 · Cited by 170 · cited 2×
“events and short follow-up, dabigatran use in VKA naive patients seems to be a safe option in our study without an increased risk of thromboembolic or bleeding events.(27) In addition, our results call for a more cautious approach when shifting high-risk patients from VKA to dabigatran treatment.”
ResultSelf-citation[Data validity and coverage in the Danish National Health Registry. A literature review].
Nickelsen, T. N. (2001) · PubMed · Cited by 168
Garber, S. T., Sivakumar, W., & Schmidt, R. H. (2012) · Journal of neurosurgery · doi:10.3171/2012.2.jns112132 · Cited by 93
Szczerba, E. (2012) · PubMed · Cited by 77
Hommel, K., Rasmussen, S., Madsen, M., & Kamper, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp571 · Cited by 73
Andersson, C., Norgaard, M. L., Hansen, P. R., Fosbøl, E. L., Schmiegelow, M., Weeke, P. E., Olesen, J. B., Raunsø, J., Jørgensen, C. H., Vaag, A. A., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq160 · Cited by 73 · cited 1×
“Comobidities and concomitant medical therapy Comorbidities of congestive heart failure, hypertension, diabetes mellitus, thromboembolism (ischaemic stroke, transitory ischaemic attack and peripheral artery embolism), vascular disease (myocardial infarction, peripheral artery disease and aortic plaque) and previous ble…”
MethodSelf-citationSalmela, B., Joutsi‐Korhonen, L., Armstrong, E., & Lassila, R. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300948 · Cited by 72 · cited 1×
“authorities for patients with non-valvular AF; however, the approval was followed by several concerns including case reports of serious bleedings(8) 9 as well as concerns about poor adherence to therapy.(10) Consequently, the Food and Drug Administration (FDA) in the USA, and European Medicine Agency (EMA) brought a s…”
BackgroundUse of sumatriptan in Denmark in 1994–5: an epidemiological analysisof nationwide prescription data
Gaist, D., Andersen, M., Aarup, A., Hallas, J., & Gram, L. F. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00582.x · Cited by 53
Fatal gastrointestinal hemorrhage after a single dose of dabigatran
Kernan, L., Ito, S., Shirazi, F., & Boesen, K. J. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.705290 · Cited by 40
Frost, L., Vukelic Andersen, L., Vestergaard, P., Husted, S., & Mortensen, L. S. (2006) · Neuroepidemiology · doi:10.1159/000092795 · Cited by 37
Cited by
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667
Data Resource Profile: The Danish National Prescription Registry
Pottegård, A., Schmidt, S. A. J., Wallach-Kildemoes, H., Sørensen, H. T., Hallas, J., & Schmidt, M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw213 · Cited by 1,431
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Vinogradova, Y., Coupland, C., Hill, T., & Hippisley-Cox, J. (2018) · BMJ · doi:10.1136/bmj.k2505 · Cited by 275
Metadata
- Authors
- Sørensen, R., Gislason, G., Torp-Pedersen, C., Olesen, J. B., Fosbøl, E. L., Hvidtfeldt, M. W., Karasoy, D., Lamberts, M., Charlot, M., Køber, L., Weeke, P., Lip, G. Y. H., & Hansen, M. L.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013
- Volume
- 3
- Issue
- 5
- Pages
- e002758
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2042608661
- Cited by
- 184
- References
- 30
- FWCI
- 23.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.